Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Riccardo Lencioni, MD, FSIR, EBIR

Dr Lencioni on the Results of the EMERALD-1 Trial in Unresectable HCC

January 19th 2024

Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.

HCC | Image Credit: © Pic4U - stock.adobe.com

Subgroup Analysis Reveals Higher Incidence of Serious TEAEs With Regorafenib in Patients With uHCC and CP-B Liver Function

January 19th 2024

Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.

Maria Reig, MD, PhD

Fostrox/Lenvatinib Combination Displays Efficacy, Tolerability in Pretreated HCC

January 19th 2024

Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.

Richard S. Finn, MD

Frontline Pembrolizumab Plus Lenvatinib Maintains Efficacy, Shows Promising DOR in Advanced HCC

January 19th 2024

Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.

© stock.adobe.com

Neoadjuvant Camrelizumab/Chemo Combo Shows Clinical Activity in Locally Advanced ESCC

January 19th 2024

Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin improved pCR vs chemotherapy alone in patients with esophageal squamous cell carcinoma.

Yelena Janjigian, MD

Neoadjuvant Durvalumab Plus Chemo Boosts pCR Vs Chemo Alone in Gastric/GEJ Cancers Regardless of Region

January 19th 2024

Durvalumab plus neoadjuvant FLOT improved pCR vs chemotherapy alone in patients with resectable gastric and GEJ cancers, irrespective of region.

Chih-Hung Hsu, MD, PhD

Tiragolumab Plus Atezolizumab and Chemotherapy Offers Survival Benefit Over Chemotherapy Alone in ESCC

January 19th 2024

Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.

Manish A. Shah, MD

Dr Shah on the 5-Year Survival Outcomes From the KEYNOTE-590 Study in Esophageal Cancer

January 19th 2024

Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.

ASKB589 Plus CAPOX and Sintilimab in Gastric/GEJ Cancers | Image Credit: © Rasi - stock.adobe.com

ASKB589 Plus CAPOX and Sintilimab Demonstrates Early Efficacy in Gastric/GEJ Cancers

January 18th 2024

ASKB589 demonstrated anti-tumor activity in combination with capecitabine and oxaliplatin plus sintilimab in gastric or gastroesophageal junction cancers.

Ian Chau, MD, FRCP

First-Line Nivolumab Plus Chemotherapy Shows Real-World Efficacy in Gastric/GEJ/Esophageal Cancers

January 18th 2024

Real-world findings demonstrated a favorable survival benefit with nivolumab plus chemotherapy in advanced gastroesophageal adenocarcinoma.

Diwakar Davar, MD, MSc

Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC

January 10th 2024

Cobolimab plus dostarlimab-gxly showed activity and acceptable safety across all dose levels assessed in patients with non–small cell lung cancer.

Christopher T. Chen, MD

Camidanlumab Tesirine Plus Pembrolizumab Produces Responses But Increases Immune Toxicities in Select Solid Tumors

January 9th 2024

Camidanlumab tesirine was well tolerated as a monotherapy and elicited responses when given with pembrolizumab in patients with advanced solid tumors.

Thomas Marron, MD, PhD

Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC

January 5th 2024

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.

Roy S. Herbst, MD, PhD

Lenvatinib/Pembrolizumab/Chemo Induces Inferior OS vs Pembrolizumab/Chemo in Previously Untreated NSCLC

January 5th 2024

Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.

Martin Wermke, MD

Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma

January 5th 2024

Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.

Melanoma - stock.adobe.com

Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma

January 5th 2024

Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.

Natasha B. Leighl, MD, BSc, MMSc

Lenvatinib Plus Pembrolizumab Fails to Improve OS and PFS Over Docetaxel in Stage IV NSCLC

January 4th 2024

Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

Niels Reinmuth, MD, PhD

LUMINANCE Data Support the Frontline Use of Durvalumab Plus Platinum/Etoposide in ES-SCLC

January 4th 2024

The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.

Benjamin Besse, MD, PhD, of Paris Saclay University at the Institut Gustave Roussy in Villejuif, France

Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC

January 4th 2024

Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.

Solange Peters, MD, PhD

POSEIDON Update Confirms OS Benefit of Tremelimumab/Durvalumab Plus Chemo in mNSCLC

January 3rd 2024

A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non­–small cell lung cancer.

Scot Ebbinghaus, MD

Vibostolimab Plus Pembrolizumab Coformulation ± Docetaxel Did Not Significantly Improve PFS in NSCLC

January 3rd 2024

A coformulation of vibostolimab and pembrolizumab with or without docetaxel failed to result in a statistically significant improvement in progression-free survival compared with docetaxel alone in patients with metastatic non­–small cell lung cancer.

Akshat Jain, MBBS

Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding Disorders

December 15th 2023

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Zanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)

Zanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)

December 15th 2023

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

Jennifer Brown, MD, PhD

Acquired BTK and PLCG2 Mutations May Not Drive Progression After Zanubrutinib/Ibrutinib Treatment in Relapsed CLL

December 14th 2023

The majority of patients with relapsed CLL treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation at the time of disease progression, indicating that these mutations may not be the primary drivers of resistance and relapse in this population.

Jennifer Brown, MD, PhD

Responses With Pirtobrutinib Remain High Despite Acquired Resistance in Relapsed CLL/SLL

December 13th 2023

Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.

DZD8586 Produces Responses in B-Cell Non-Hodgkin Lymphoma

DZD8586 Demonstrates Responses Across Dose Levels in B-Cell Non-Hodgkin Lymphoma

December 13th 2023

DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.

Asciminib Elicits Safe and Durable Responses in Previously Treated CML

Asciminib Elicits Safe and Durable Responses in Previously Treated CML

December 12th 2023

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.

Elizabeth K. O’Donnell, MD

Isa-KRd Produces Deep, Durable Response Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

December 12th 2023

The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.

Allison J. Moskowitz, MD

Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL

December 12th 2023

Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.